RALLYBIO CORP (RLYB) Stock Price & Overview
NASDAQ:RLYB • US75120L2097
Current stock price
The current stock price of RLYB is 8.3 USD. Today RLYB is down by -1.66%. In the past month the price decreased by -12.63%. In the past year, price increased by 315%.
RLYB Key Statistics
- Market Cap
- 43.907M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.59
- Dividend Yield
- N/A
RLYB Stock Performance
RLYB Stock Chart
RLYB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB is one of the better performing stocks in the market, outperforming 98.4% of all stocks.
RLYB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLYB. RLYB has a great financial health rating, but its profitability evaluates not so good.
RLYB Earnings
On March 16, 2026 RLYB reported an EPS of -1.03 and a revenue of 222.00K. The company beat EPS expectations (13.94% surprise) and beat revenue expectations (63.24% surprise).
RLYB Forecast & Estimates
7 analysts have analysed RLYB and the average price target is 8.16 USD. This implies a price decrease of -1.69% is expected in the next year compared to the current price of 8.3.
For the next year, analysts expect an EPS growth of 11.88% and a revenue growth -100% for RLYB
RLYB Groups
Sector & Classification
RLYB Financial Highlights
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -5.59. The EPS increased by 48.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.42% | ||
| ROE | -15.49% | ||
| Debt/Equity | 0 |
RLYB Ownership
RLYB Latest News, Press Relases and Analysis
RLYB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RLYB
Company Profile
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Company Info
IPO: 2021-07-29
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 15
Phone: 13026365400
RALLYBIO CORP / RLYB FAQ
What does RLYB do?
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
What is the current price of RLYB stock?
The current stock price of RLYB is 8.3 USD. The price decreased by -1.66% in the last trading session.
Does RALLYBIO CORP pay dividends?
RLYB does not pay a dividend.
What is the ChartMill technical and fundamental rating of RLYB stock?
RLYB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of RALLYBIO CORP (RLYB)?
RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.59).
How many employees does RALLYBIO CORP have?
RALLYBIO CORP (RLYB) currently has 15 employees.
What is the market capitalization of RLYB stock?
RALLYBIO CORP (RLYB) has a market capitalization of 43.91M USD. This makes RLYB a Nano Cap stock.